and later we'll find out board was selling at $5.25, which could drive the stock even lower. Board is this stocks worst enemy. Every month board sells and drives the stock even lower. Board not shorts are driving the stock down. Just look at form 4 insider sells at the end of every month and you'll see 1 million shares were sold by board.
and companies know its unprofitable why would companies want to fork over big bucks for it.
yet the stock has gone down from nearly $11 to $5.25. Explain why this happened idiots.
nope I blame insiders who say the stock is worth so much more yet sell every month and not just tax tales large blocks of stock.
i don'r know why doesn't afrezza make commercials and do PR explaining it
$4 very soon. in a recent survey of 100 diabetics on Research Now’s diabetes panel, 91% of respondents were not even aware of Afrezza. No advertising, no PR no one will know about Afrezza
a drug that doesn't advertise, does no pr. They keep calling it a blockbuster but I see no advertising of any kind for it. No PR, no advertising =death for drugs. I can't turn on the TV, read an news paper or magazine or go on the net without seeing advertising for drugs. But MNKD which claims Afrezza is a blockbuster does no advertising and no pr.
right now I don't assume. I know the stock is worth $6 tops. I will buy at 4 and sell at $6. Otherwise I have no interest in this pos.
Why wouldn't they slide? no one knows about afrezza.
You can't turn the TV on or read a magazine or even go on the net without seeing a commercial for a new drug. With the money they spend on R&D, they need sales to start talking off right away. Right now mnkd is 1 billion dollars in the red. But they don't need to spend money on advertising and PR. Sanofi does. If they didn't have the supply needed to launch the product. They shouldn't have launched the product. It makes no sense that they have a business partner with big bucks and have no supply, no advertising and no pr and it makes even less sense that most diabetics polled have never even heard of Afrezza. Sanofi has big bucks and those big bucks should have been spent to get enough supply for this to be a blockbuster drug. Sating there's not enough supply to meet the demand that advertising and PR would create is just BS.
you are as much of an idiot as the people on this message board saying mnkd is going to $12 or above. By the way, I don't have a position in mnkd, but will add one if he goes to $4 or below. Then I will sell at $5.50.